Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (720)	7/13/1999 4:03:00 PM
From: Cheeseburger	Read Replies (1) \| Respond to of 900

Hambrecht & Quist reiterates buy, possible upside surprise for quarter, estimate $0.04 ,,, nordby.com Also ,,, Peter, I truly feel that my projections of EVACET sales are conservative. LIPO will team up with a partner to maximize sales outside of the U.S. From my personal discussions with many oncologists who attended the ASCO presentation of the EVACET data, the reception of the data was overwhelmingly positive. I believe that the conversion of the standard dox. market will be quicker than stated in my forecast therefore resulting in higher worldwide sales.